and the related t(16;161(p13;q22) are seen in a subset of acute myelogenous leukemia (AML) phenotypically and prognostically differing from other cases. We have recently shown that inv(l6) results in fusion of CBFB/P€6P2B, a gene encoded at 16q22 t o M V H l l, a smooth muscle myosin heavy chain gene encoded at 16~13. Chimeric transcripts consisting of upstream CBW fused to downstream M V H l 1 coding sequences result from this fusion. In this study we have examined a series of 37 of these cases using reverse transcriptase-polymerase chain reaction (RT-PCR) to detect expression of a hybrid CBFB/MVH11 transcript. Chimeric cDNAs were detected in all but 1 of 37 leukemias with typical ECURRING CHROMOSOME abnormalities in malignant diseases are closely associated with particular tumor phenotypes.' This is particularly true of structural chromosomal changes seen in the leukemias and lymphomas, in which they have diagnostic and prognostic implications. Molecular analysis of chromosomal translocations in malignancy has yielded important insights into disease pathogenesis and normal cellular physiology. Molecular assays have provided more precise definition of disease subsets, thus aiding in the management of patients with these rearrangements.* In cases where there is sufficient molecular information, reverse transcriptase-polymerase chain reaction analysis of RNA (RT-PCR) has been particularly useful for monitoring of minimal residual disease states in patients having achieved complete remission after induction therapy for acute and chronic leukemia^.^,^
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0 1994 by The American Sociely of Hematology. has been found to be associated with a relatively good prognosis for long-term disease-free s u r~i v a l .~~~ The related change t( 16; 16)(p13;q22) is found in similar patients.'. ' We recently described yeast artificial chromosome cloning and the molecular mapping of 16p-arm breakpoints. ' Subsequently, we have cloned the 16p-arm and the q-arm breakpoints and cDNAs corresponding to genes encoded at each site.' A gene encoding a smooth muscle myosin protein, designated MYHII, has been shown to be located at, and interrupted by, the p13 breakpoint.' Though originally thought to be encoded at 16q12,"' we have recently confirmed the 1 6~1 3 mapping of MYHII." CBFB, the human homologue of the murine CBFIPEBPZ viral enhancer binding factor @ subunit gene, has been shown to be located at the q22 breakpoint. The murine CBFP/PEBPZp gene has been independently cloned by two separate Its gene product forms a heterodimeric transcription factor that binds to viral promoters in the murine leukemia virus long terminal repeat (MMLV-LTR) and in the human polyoma virus enhancer. Our work has shown that the inv(l6) generates a chimeric messenger RNA transcript by fusing the human CBFB gene upstream of a major portion of MYHII.' This finding is of particular interest because the murine CBFa subunit gene is the homologue of the human AMLl gene involved in the t(8; 2 I ) translocation of AML M2 subtype.''.lh
We report here the RT-PCR study of a series of 37 AML cases of inv( 16) and the related translocation t( 16; 16), and 10 cases of AML without chromosome 16 changes. All but I of the typical inv(l6) cases and all translocation cases are shown to have fusion of upstream CBFB coding sequences to downstream MYHlI coding sequences. The molecular consequences of t( 16; 16) are thus shown to be similar to those of invl6. Four different fusion forms are efficiently amplified with two primer sets. We show that nearly all of the CBFB coding sequence is included in the fusion transcripts. The assay is shown to be highly sensitive and to detect leukemia during morphologic remission. PCR products were separated on 2% agarose gels, stained with ethidium bromide. For most experiments products were transferred to nylon membranes and hybridized at 55°C to oligonucleotide probes as described.I7 PCR products to be used for sequencing were gel purified before direct sequencing on an Applied Biosciences Inc (Foster City, CA) automated sequencer using the PCR primers described above. Oligonucleotides were designed using the O L E O version 3.4 primer software (National Biosciences, Plymouth, MN). Primers and probes used are shown in Table 1 . Their relative positions and sources may be seen in Fig 1. (Fig 2A) . Amplification of larger chimeric fragments (types B, C, and D) with primers 1 and 2M was frequently seen but was found to be unreliable. For this reason new primers 3 and 4 were designed and used for amplification of these cases (Fig 2B) . One case showed type B fusion, four type C, and two type D.
MATERIALS AND METHODS

Materials
RESULTS
Amplification of
In all cases, including the two that failed to show any amplified product, cDNA was amplified with /3actin" specific primers to demonstrate that cDNA had been synthesized (not shown). Review of the karyotype of these two nonamplifying cases showed that one patient (mentioned above) in fact had chronic myelogenous leukemia (CML) in blast crisis with 9% of metaphase cells showing inv(16)(p13;q24). Thus, in this case the inv(l6) chromosome clearly had a q arm breakpoint differing from the q22 breakpoint seen in other cases. The second nonamplifying sample (case 28) had the typical inv(l6) but was one of only two cases that had been cryopreserved as cell pellets (ie, not viably frozen) for more than 10 years.
To verify that all major amplified bands in fact contained coding sequence for the CBFB gene, these products were transferred to membrane and probed with a radiolabeled CBFB-specific oligonucleotide probe ( Table 1) In this case BM eosinophils were elevated but their morphology was considered normal.
hybridize to probe (eg, Fig 2A, lane 1 and Fig 2B, lane 3) . Blots were also hybridized to an oligonucleotide probe for MYHl I sequences with similar results (oligonucleotide P3, Table I [not shown]). The characterization of cDNAs A, C, and D by sequencing has been described.' The form we designate B was encountered only in one case. Amplification of this case with primers 1 and 2M produced a fragment of 900 bp, whereas primers 3 and 4 generated a 221-bp fragment (Fig 2, lane 2) . Direct sequencing of cDNA from this case showed fusion of CBFB at position 495' to M Y H l l at position 1528.'' The CBFB fusion point is the same as that for types A, C, and D. All four forms may be predicted to generate in frame translation of M Y H l l downstream coding sequences.
It should be noted that all seven cases of t(16; 16) (p 13; q22) showed amplifiable chimeric CBFBMYHI 1 transcript. Six cases had type A cDNA product and one had type D.
Two of our cases with inv(l6) did not have AML as defined by accepted criteria. Case 13 had refractory anemia with excess blasts in transformation. The finding of inv( 16) in cases of this kind is well re~ognized.~ In case 20 inv(l6) was found at the time of blast crisis of CML as was recently reported for another case.*' By our analysis the CBFB/ M Y H l l chimeric transcripts would seem to be similar in these cases to those in typical AML cases with M4Eo.
A series of IO AMLs without chromosome 16 abnormalities was studied using both primer sets as above. Though actin bands amplified strongly in each case, no CBFB/ M Y H l l chimeric product could be demonstrated after transfer and hybridization of gene-specific probes.
Amplijcation of MYHl1 and upstream CBFB chimeric fragments. To confirm that these cases expressed all of the expected CBFB cDNA coding sequence upstream of M Y H I I , primers were designed for upstream CBFB based on the published murine CBFP sequences." The initial ATG codon of the long open reading frame was included in these primers, designated A and B, so that all CBFB coding sequence included in the chimeric transcript would be amplified. The location of primers A and B is shown in Fig 1. When these primers were used in combination with primer 2M, two cases with type A and one type C transcripts all showed prominent amplified bands of sizes predicted from their previous shorter amplification products." As shown in Fig 3, lanes 4.6, and 8 , in each case the amplified band with primer A used with 2M was shown to be 270 bp longer than the band amplified from the original primer set ( I and 2M). Primer B used with 2M showed a slightly shorter fragment as expected from its position 15 bp downstream of A (Fig   3, lanes 5, 7, and 9 ).
PCR products from the two type A cases were sequenced 200 bp from each end, confirming sequence identity of upstream sequences to CBFB.' Thus, it is shown that in these cases the full-length CBFB coding sequence upstream of the originally identified breakpoint is included in chimeric transcripts. It must be noted that point mutations within unsequenced portions of the transcript have not been excluded. Available data predict that all but 17 amino acids of the normal CBFB protein should be included in the CBFB/ MYH I 1 fusion protein.
Determinntion qf sensitivity qf nmpl$cation and studv of rcvnission samples f.r chimeric trmscripts. Experiments using inv( 16) RNA in serial dilutions were conducted to determine the level of sensitivity of breakpoint sequence amplification. As shown in Fig 4A, type A fusion transcripts are amplifiable from cDNA synthesized from as little as 20 pg of total cellular RNA. This quantity of RNA is equivalent to the 2-5 cell level.
Three samples from different patients in varying stages of remission from inv( 16) AML have been studied with PCR primers I and 2M. Two of these three patients were in remission for more than I year and showed no amplified chimeric transcript. The third patient was studied at day 21 after treatment after relapse, but at the time of morphologic remission (total marrow blasts 1%) shows amplification of a chimeric band. This is shown in Fig 4B . Although the reciprocal fusion gene MVHllC6fE may also be generated in some cases, deletion of M Y H l l sequences upstream of the breakpoint appears to be present in other casesg (manuscript in preparation). We have shown that RT-PCR amplification of the type A CBFBLUYHII transcripts is highly sensitive and reproducible. It appears that this assay may be useful for the prospective clinical monitoring of patients with invl6. Longitudinal studies assessing the reliability of detection of fusion transcript during remission will be necessary to determine the predictive value of the assay for relapse. It is unclear how frequently patients will show amplification during remission. In AML with t(8;21) there are reports of RT-PCR positivity years after remission induction at times of low probability of rela~se.4,'~ It is clear from these reports and studies of BCRLABL after allogeneic BM transplantation*' that the finding of rare residual fusion transcripts during clinical remission of leukemias does not indicate impending relapse.
The observation of the participation of CBFB in a chimeric gene is striking in view of findings of the involvement of the AMLl gene in t(8;21). These two genes encode products which in normal cells bind together to form the heterodimeric transcription factor CBFPEBP2. Little is known at present of the physiologic role of this factor. It is clearly expressed in murine T-cell lines and those of certain other hematopoietic lineages." In addition to binding to the enhancers of the MMLV-LTRZ3 and the human polyoma v i r~s , 2~ the human T-cell receptor and CD2 and CD3 enhancers appear to be normal binding sites." Studies of the murine fibroblastoid line NIH3T3 suggest CBFPEPB2 expression and binding to ''core" DNA recognition sequence^.'^ Thus, it seems very likeiy that other genomic sequence targets are involved in the mediation of this factor's activity.
The cellular consequences of expression of CBFB/ MYHl1 fusion protein remain to be defined. Nearly all of the CBFB coding sequence is included. Thus, it seems very likely that this abnormal gene product is functioning at least in part via alteration of DNA binding of the CBFPEBP2 transcription factor.
